A Phase 1 interventional study of MT-1186 and MT-1186-matching placebo in Healthy Adult Subjects, sponsored by Shionogi. Completed at 1 site in Japan. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Shionogi · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the pharmacokinetics safety, and tolerability of single and multiple doses of edaravone solution and suspension in healthy adult males
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional screening criteria check may apply for qualification:
Exclusion Criteria:
Additional screening criteria check may apply for qualification:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
Drug: MT-1186 · Drug: MT-1186-matching placebo
Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
Drug: MT-1186 · Drug: MT-1186-matching placebo
Healthy Japanese male subjects receive doses of MT-1186 or matching placebo.
Drug: MT-1186 · Drug: MT-1186-matching placebo
Healthy Japanese male subjects receive doses of MT-1186 or matching placebo.
Drug: MT-1186 · Drug: MT-1186-matching placebo
Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
Drug: MT-1186 · Drug: MT-1186-matching placebo
Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
Drug: MT-1186 · Drug: MT-1186-matching placebo
Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
Drug: MT-1186 · Drug: MT-1186-matching placebo
Healthy Caucasian male subjects receive a single dose of MT-1186 or matching placebo.
Drug: MT-1186 · Drug: MT-1186-matching placebo
Healthy Japanese male subjects receive multiple doses of MT-1186 or matching placebo.
Drug: MT-1186 · Drug: MT-1186-matching placebo
Healthy Japanese male subjects receive multiple doses of MT-1186 or matching placebo
Drug: MT-1186 · Drug: MT-1186-matching placebo
Solution or suspension
Also known as: Edaravone
Solution or suspension
Number of Participants With Adverse Events (Aes) and Adverse Drug Reactions (ADRs)
Time frame: Day 1 to 8 in Part 1, up to 12 days in Part 2
Area Under the Concentration Versus Time Curve (AUC) of Unchanged Edaravone
Area under the plasma concentration versus time curve from time zero up to 24 hours (AUC0-24) of unchanged edaravone.
Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Area Under the Concentration Versus Time Curve (AUC) of Sulfate Conjugate
Area under the plasma concentration versus time curve from time zero up to 24 hours (AUC0-24) of sulfate conjugate.
Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Area Under the Concentration Versus Time Curve (AUC) of Glucuronide Conjugate
Area under the plasma concentration versus time curve from time zero up to 24 hours (AUC0-24) of glucuronide conjugate.
Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Maximum Plasma Concentration (Cmax) of Unchanged Edaravone
Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Maximum Plasma Concentration (Cmax) of Sulfate Conjugate
Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Maximum Plasma Concentration (Cmax) of Glucuronide Conjugate
Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Part 2: Minimum Plasma Concentration at Steady State (Ctrough, ss)
Time frame: Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Time to Reach Maximum Plasma Concentration (Tmax) of Unchanged Edaravone
Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Time to Reach Maximum Plasma Concentration (Tmax) of Sulfate Conjugate
Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Time to Reach Maximum Plasma Concentration (Tmax) of Glucuronide Conjugate
Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Terminal Elimination Half-life (t1/2) of Unchanged Edaravone
Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Terminal Elimination Half-life (t1/2) of Sulfate Conjugate
Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Terminal Elimination Half-life (t1/2) of Glucuronide Conjugate
Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Lambda-z of Unchanged Edaravone
Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Lambda-z of Sulfate Conjugate
Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Lambda-z of Glucuronide Conjugate
Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Mean Residence Time (MRT) of Unchanged Edaravone
Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Apparent Total Clearance (CL/F) of Unchanged Edaravone
Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Apparent Distribution Volume at Elimination Phase (Vz/F) and Apparent Distribution Volume at Steady State (Vss/F) of Unchanged Edaravone
Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Change of Heart Rate (HR) From Baseline
Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6. Baseline is calculated as average HR from 0.75, 0.5, and 0.25 hours pre-dose.
Time frame: 0.75, 0.5, and 0.25 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose.
Change of PR Interval (PR) From Baseline
Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6. Baseline is calculated as average HR from 0.75, 0.5, and 0.25 hours pre-dose.
Time frame: 0.75, 0.5, and 0.25 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose.
Change of QTcF Interval (QTcF) From Baseline
Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6. Baseline is calculated as average HR from 0.75, 0.5, and 0.25 hours pre-dose.
Time frame: 0.75, 0.5, and 0.25 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose.
Change of QRS Duration (QRS) From Baseline
Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6.
Time frame: 0.75, 0.5, and 0.25 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose.
| Milestone | A Single Dose MT-1186 (Part 1, Cohort S1) | A Single Dose MT-1186 (Part 1, Cohort S2) | A Single Dose MT-1186 (Part 1, Cohort S3) | A Single Dose MT-1186 (Part 1, Cohort S4) | A Single Dose MT-1186 (Part 1, Cohort S5) | A Single Dose MT-1186 (Part 1, Cohort S6) | A Single Dose MT-1186 (Part 1, Cohort S7) | Matching Placebo (a Single Dose Cohorts) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) | Matching Placebo (Multiple Doses Cohorts) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 14 | 6 | 6 | 6 |
| Completed | 6 | 6 | 5 | 6 | 6 | 6 | 6 | 14 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | A Single Dose MT-1186 (Part 1, Cohort S1) | A Single Dose MT-1186 (Part 1, Cohort S2) | A Single Dose MT-1186 (Part 1, Cohort S3) | A Single Dose MT-1186 (Part 1, Cohort S4) | A Single Dose MT-1186 (Part 1, Cohort S5) | A Single Dose MT-1186 (Part 1, Cohort S6) | A Single Dose MT-1186 (Part 1, Cohort S7) | Matching Placebo (a Single Dose Cohorts) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) | Matching Placebo (Multiple Doses Cohorts) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) | Matching Placebo (Multiple Doses Cohorts) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Participants with AEs | 0 | 2 | 3 | 0 | 0 | 1 | 1 | 2 | 2 | 2 | 1 | 1 |
| Participants with ADRs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Area under the plasma concentration versus time curve from time zero up to 24 hours (AUC0-24) of unchanged edaravone.
| ng*h/mL | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|---|---|---|---|---|---|---|---|
| AUC from time zero to 24 hour (AUC 0-24): Day 1 | 816 ± 231 | 2242 ± 911 | 6254 ± 1236 | 2443 ± 813 | 11319 ± 1053 | 9034 ± 2738 | 285 ± 113 | 4935 ± 1980 | 1917 ± 383 | 4133 ± 1260 |
| AUC from time zero to 24 hour (AUC 0-24): Day 5, only Part 2 | — | — | — | — | — | — | — | — | 2189 ± 516 | 4279 ± 1166 |
Area under the plasma concentration versus time curve from time zero up to 24 hours (AUC0-24) of sulfate conjugate.
| ng*h/mL | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|---|---|---|---|---|---|---|---|
| AUC from time zero to 24 hour (AUC 0-24): Day 1 | 16251 ± 7143 | 30004 ± 6103 | 45666 ± 10447 | 38244 ± 4602 | 67693 ± 14170 | 68126 ± 15067 | 6709 ± 2171 | 44797 ± 16374 | 26132 ± 4083 | 39516 ± 3331 |
| AUC from time zero to 24 hour (AUC 0-24): Day 5, only part 2 | — | — | — | — | — | — | — | — | 24578 ± 4186 | 39102 ± 4208 |
Area under the plasma concentration versus time curve from time zero up to 24 hours (AUC0-24) of glucuronide conjugate.
| ng*h/mL | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|---|---|---|---|---|---|---|---|
| AUC from time zero to 24 hour (AUC 0-24):Day 1 | 2360 ± 648 | 4815 ± 910 | 8146 ± 1275 | 7406 ± 1368 | 14403 ± 1557 | 12499 ± 3457 | 1201 ± 454 | 8038 ± 1898 | 4806 ± 509 | 7932 ± 1190 |
| AUC from time zero to 24 hour (AUC 0-24): Day 5, only part 2 | — | — | — | — | — | — | — | — | 4698 ± 499 | 8059 ± 1278 |
| ng/mL | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 755 ± 356 | 1735 ± 738 | 4933 ± 1268 | 899 ± 464 | 8805 ± 933 | 5426 ± 2496 | 208 ± 112 | 3692 ± 1529 | 1953 ± 838 | 3855 ± 1676 |
| Day 5 | — | — | — | — | — | — | — | — | 2308 ± 941 | 4092 ± 1715 |
| ng/mL | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 5481 ± 2337 | 9108 ± 2104 | 12190 ± 2087 | 7324 ± 743 | 14590 ± 2102 | 14080 ± 4787 | 2913 ± 870 | 11510 ± 2502 | 7318 ± 612 | 10830 ± 2346 |
| Day 5 | — | — | — | — | — | — | — | — | 7402 ± 954 | 11200 ± 1744 |
| ng/mL | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 1313 ± 378 | 2272 ± 279 | 3507 ± 158 | 1893 ± 358 | 5322 ± 958 | 3968 ± 912 | 750 ± 263 | 3361 ± 1183 | 2145 ± 356 | 3219 ± 666 |
| Day 5 | — | — | — | — | — | — | — | — | 2209 ± 156 | 3439 ± 428 |
| ng/mL | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|
| Unchanged Edaravone | 2.34 ± 0.30 | 3.79 ± 0.80 |
| Sulfate conjugate | 32.91 ± 9.01 | 49.98 ± 11.22 |
| Glucuronide conjugate | 2.69 ± 0.30 | 5.48 ± 1.90 |
| h | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 0.3 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 | 1.4 ± 1.6 | 0.6 ± 0.3 | 0.8 ± 0.4 | 0.4 ± 0.1 | 0.6 ± 0.3 | 0.4 ± 0.1 | 0.4 ± 0.1 |
| Day 5 | — | — | — | — | — | — | — | — | 0.4 ± 0.1 | 0.4 ± 0.1 |
| h | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 0.6 ± 0.2 | 0.8 ± 0.3 | 1.0 ± 0.0 | 1.3 ± 0.5 | 1.3 ± 0.3 | 1.4 ± 0.4 | 0.5 ± 0.3 | 0.9 ± 0.4 | 0.8 ± 0.3 | 0.9 ± 0.2 |
| Day 5 | — | — | — | — | — | — | — | — | 0.8 ± 0.3 | 0.8 ± 0.3 |
| h | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 0.5 ± 0.3 | 0.6 ± 0.2 | 0.6 ± 0.2 | 1.2 ± 0.6 | 1.0 ± 0.3 | 1.1 ± 0.4 | 0.5 ± 0.3 | 0.9 ± 0.4 | 0.7 ± 0.3 | 0.6 ± 0.2 |
| Day 5 | — | — | — | — | — | — | — | — | 0.6 ± 0.2 | 0.7 ± 0.3 |
| h | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 3.2 ± 0.9 | 5.1 ± 1.5 | 9.1 ± 2.4 | 5.2 ± 1.7 | 11.8 ± 4. | 9.1 ± 3.3 | 2.4 ± 0.7 | 6.5 ± 1.7 | 4.6 ± 0.4 | 4.2 ± 0.2 |
| Day 5 | — | — | — | — | — | — | — | — | 8.7 ± 3.2 | 12.4 ± 1.9 |
| h | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 7.9 ± 2.6 | 7.3 ± 2.6 | 5.9 ± 1.7 | 5.1 ± 1.3 | 6.0 ± 1.6 | 4.9 ± 0.3 | 5.2 ± 0.6 | 6.4 ± 2.6 | 3.7 ± 0.2 | 3.4 ± 0.3 |
| Day 5 | — | — | — | — | — | — | — | — | 6.2 ± 0.4 | 6.8 ± 1.0 |
| h | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 3.4 ± 1.1 | 3.2 ± 0.9 | 4.3 ± 0.7 | 3.8 ± 0.9 | 5.9 ± 1.4 | 4.8 ± 0.5 | 2.8 ± 0.9 | 4.7 ± 1.2 | 3.5 ± 0.2 | 3.2 ± 0.4 |
| Day 5 | — | — | — | — | — | — | — | — | 3.9 ± 0.3 | 5.2 ± 2.0 |
| 1/h | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 0.23 ± 0.05 | 0.14 ± 0.03 | 0.08 ± 0.02 | 0.14 ± 0.04 | 0.07 ± 0.02 | 0.08 ± 0.02 | 0.31 ± 0.11 | 0.11 ± 0.03 | 0.15 ± 0.01 | 0.17 ± 0.01 |
| Day 5 | — | — | — | — | — | — | — | — | 0.09 ± 0.03 | 0.06 ± 0.01 |
| 1/h | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 0.10 ± 0.03 | 0.11 ± 0.04 | 0.12 ± 0.02 | 0.14 ± 0.03 | 0.12 ± 0.03 | 0.14 ± 0.01 | 0.14 ± 0.02 | 0.12 ± 0.03 | 0.19 ± 0.01 | 0.20 ± 0.02 |
| Day 5 | — | — | — | — | — | — | — | — | 0.11 ± 0.01 | 0.10 ± 0.02 |
| 1/h | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 0.23 ± 0.09 | 0.23 ± 0.07 | 0.17 ± 0.03 | 0.19 ± 0.05 | 0.12 ± 0.02 | 0.15 ± 0.01 | 0.27 ± 0.07 | 0.16 ± 0.04 | 0.20 ± 0.01 | 0.22 ± 0.03 |
| Day 5 | — | — | — | — | — | — | — | — | 0.18 ± 0.01 | 0.15 ± 0.05 |
| h | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 1.92 ± 0.46 | 2.07 ± 0.26 | 1.98 ± 0.15 | 3.41 ± 0.62 | 2.14 ± 0.20 | 2.42 ± 0.45 | 2.02 ± 0.20 | 2.02 ± 0.32 | 1.94 ± 0.15 | 1.90 ± 0.26 |
| Day 5 | — | — | — | — | — | — | — | — | 2.17 ± 0.24 | 2.28 ± 0.37 |
| L/h | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 79.77 ± 26.21 | 60.29 ± 22.90 | 32.73 ± 6.42 | 87.07 ± 22.96 | 26.42 ± 2.30 | 36.11 ± 13.62 | 119.41 ± 43.64 | 46.72 ± 20.27 | 64.51 ± 11.64 | 53.40 ± 20.46 |
| Day 5 | — | — | — | — | — | — | — | — | 57.64 ± 14.54 | 50.74 ± 18.08 |
| L | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) | A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) |
|---|---|---|---|---|---|---|---|---|---|---|
| Vz/F (Part 1), Vss/F (Part 2): Day1 | 348.98 ± 87.82 | 422.67 ± 126.97 | 426.49 ± 130.84 | 620.73 ± 139.24 | 457.99 ± 188.01 | 457.37 ± 175.69 | 384.51 ± 96.92 | 408.95 ± 121.29 | 126.41 ± 29.65 | 105.90 ± 57.04 |
| Vss/F (only Part 2): Day 5 | — | — | — | — | — | — | — | — | 125.94 ± 40.36 | 121.32 ± 66.83 |
Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6. Baseline is calculated as average HR from 0.75, 0.5, and 0.25 hours pre-dose.
| bpm | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | Matching Placebo (a Sngle Dose Cohorts |
|---|---|---|---|---|
| 0.25h | 1.8 ± 0.91 | -1.2 ± 0.91 | 1.8 ± 0.96 | -0.2 ± 0.92 |
| 0.5h | -0.2 ± 1.01 | 0.2 ± 1.01 | 1.3 ± 1.06 | 1.2 ± 1.02 |
| 1h | -0.1 ± 1.28 | -1.7 ± 1.28 | 0.2 ± 1.34 | -0.2 ± 1.29 |
| 1.5h | -1.2 ± 1.00 | -0.3 ± 1.00 | 0.2 ± 1.04 | -0.1 ± 1.01 |
| 2h | -0.1 ± 0.95 | 0.4 ± 0.95 | 0.9 ± 0.99 | -0.1 ± 0.96 |
| 4h | -0.7 ± 1.36 | -1.6 ± 1.36 | -0.1 ± 1.42 | -1.5 ± 1.37 |
| 6h | 3.2 ± 1.88 | 6.4 ± 1.87 | 3.8 ± 1.96 | 3.8 ± 1.89 |
| 8h | 4.4 ± 1.72 | 4.1 ± 1.72 | 6.2 ± 1.80 | 3.4 ± 1.74 |
| 12h | 1.9 ± 2.07 | 10.1 ± 2.07 | 7.6 ± 2.16 | 4.6 ± 2.09 |
| 24h | 1.3 ± 1.54 | 1.7 ± 1.54 | 2.2 ± 1.61 | -1 ± 1.55 |
| 36h | 8.1 ± 3.07 | 9.9 ± 3.06 | 13.2 ± 3.21 | 5.7 ± 3.10 |
| 48h | 4.3 ± 2.51 | 8.2 ± 2.51 | 8.4 ± 2.62 | 2.4 ± 2.53 |
Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6. Baseline is calculated as average HR from 0.75, 0.5, and 0.25 hours pre-dose.
| msec | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | Matching Placebo (a Sngle Dose Cohorts |
|---|---|---|---|---|
| 0.25h | -6.8 ± 1.91 | -3.3 ± 1.99 | -5.7 ± 1.92 | -4.5 ± 2.06 |
| 0.5h | -4.2 ± 1.35 | 0.1 ± 1.40 | -2.4 ± 1.36 | -3.4 ± 1.45 |
| 1h | -4.2 ± 1.68 | 2.1 ± 1.74 | -4.0 ± 1.68 | -4.7 ± 1.80 |
| 1.5h | -5.2 ± 2.23 | 0.0 ± 2.31 | -4.8 ± 2.24 | -5.3 ± 2.40 |
| 2h | -5.9 ± 1.90 | -0.8 ± 1.97 | -4.5 ± 1.91 | -5.9 ± 2.05 |
| 4h | -3.0 ± 2.64 | -3.0 ± 2.74 | -5.3 ± 2.66 | -5.4 ± 2.85 |
| 6h | -5.5 ± 1.91 | -9.6 ± 1.98 | -6.3 ± 1.92 | -6.6 ± 2.06 |
| 8h | -11.6 ± 2.60 | -9.0 ± 2.70 | -9.9 ± 2.62 | -11.9 ± 2.80 |
| 12h | -6.6 ± 3.91 | -12.0 ± 4.06 | -9.0 ± 3.93 | -11.8 ± 4.21 |
| 24h | -2.1 ± 2.62 | -1.6 ± 2.72 | -8.9 ± 2.63 | -1.1 ± 2.82 |
| 36h | -5.7 ± 3.77 | -6.8 ± 3.91 | -6.2 ± 3.78 | -9.5 ± 4.06 |
| 48h | -3.3 ± 2.63 | 0.6 ± 2.73 | -3.2 ± 2.64 | -5.4 ± 2.83 |
Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6. Baseline is calculated as average HR from 0.75, 0.5, and 0.25 hours pre-dose.
| msec | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | Matching Placebo (a Sngle Dose Cohorts |
|---|---|---|---|---|
| 0.25h | 2.0 ± 1.60 | 0.7 ± 1.60 | 1.6 ± 1.63 | 0.8 ± 1.71 |
| 0.5h | -2.2 ± 1.32 | 1.1 ± 1.31 | -3.8 ± 1.34 | -4.9 ± 1.41 |
| 1h | 0.3 ± 2.02 | -0.1 ± 2.02 | -4.7 ± 2.06 | 0.5 ± 2.17 |
| 1.5h | -5.2 ± 2.23 | 2.7 ± 1.68 | -1.9 ± 1.71 | -5.3 ± 2.40 |
| 2h | 1.2 ± 1.68 | 1.5 ± 2.34 | -5.1 ± 2.39 | 0.8 ± 1.80 |
| 4h | 2.3 ± 2.85 | -0.9 ± 2.85 | 1.4 ± 2.90 | 0.7 ± 3.06 |
| 6h | -5.7 ± 2.96 | -2.9 ± 2.96 | -7.6 ± 3.01 | -2.4 ± 3.18 |
| 8h | -5.3 ± 2.62 | -2.9 ± 2.62 | -7.0 ± 2.66 | -6.9 ± 2.81 |
| 12h | -2.3 ± 2.42 | -4.0 ± 2.42 | -3.1 ± 2.47 | -3.3 ± 2.6 |
| 24h | 2.0 ± 2.42 | -1.2 ± 2.42 | -5.7 ± 2.46 | -3.1 ± 2.60 |
| 36h | -3.0 ± 2.96 | -5.0 ± 2.96 | -5.1 ± 3.01 | -1.4 ± 3.18 |
| 48h | -1.0 ± 3.22 | -1.5 ± 3.22 | -4.4 ± 3.28 | -0.1 ± 3.46 |
Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6.
| msec | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) | A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) | Matching Placebo (a Sngle Dose Cohorts |
|---|---|---|---|---|
| 0.25h | -0.7 ± 0.85 | -0.4 ± 0.84 | 0.4 ± 0.87 | -2.0 ± 0.88 |
| 0.5h | -0.3 ± 0.77 | -0.8 ± 0.77 | -0.5 ± 0.80 | -1.6 ± 0.80 |
| 1h | -0.3 ± 0.70 | -1.5 ± 0.69 | 0.5 ± 0.72 | -1.4 ± 0.72 |
| 1.5h | -0.4 ± 0.70 | -0.7 ± 0.80 | 0.4 ± 0.83 | -1.4 ± 0.72 |
| 2h | -1.5 ± 0.98 | -0.5 ± 0.98 | 0.2 ± 1.01 | -2.7 ± 1.02 |
| 4h | -0.5 ± 1.36 | -2.1 ± 1.36 | -0.4 ± 1.41 | -0.5 ± 1.42 |
| 6h | -0.3 ± 1.31 | 1.1 ± 1.31 | -0.8 ± 1.36 | 0.7 ± 1.37 |
| 8h | -1.2 ± 1.50 | 0.0 ± 1.50 | -2.4 ± 1.55 | -1.3 ± 1.57 |
| 12h | 0.4 ± 1.71 | -2.1 ± 1.71 | -2.0 ± 1.77 | 0.0 ± 1.78 |
| 24h | -0.9 ± 1.26 | -2.2 ± 1.25 | -1.4 ± 1.30 | -1.2 ± 1.31 |
| 36h | -0.2 ± 1.76 | -1.5 ± 1.75 | -2.4 ± 1.81 | 0.4 ± 1.83 |
| 48h | -1.7 ± 1.18 | -1.5 ± 1.17 | -1.4 ± 1.22 | -0.1 ± 1.23 |
Collected over 8 days in part 1, 12 days in part 2. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A Single Dose MT-1186 (Part 1, Cohort S1) | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| A Single Dose MT-1186 (Part 1, Cohort S2) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| A Single Dose MT-1186 (Part 1, Cohort S3) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| A Single Dose MT-1186 (Part 1, Cohort S4) | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| A Single Dose MT-1186 (Part 1, Cohort S5) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| A Single Dose MT-1186 (Part 1, Cohort S6) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| A Single Dose MT-1186 (Part 1, Cohort S7) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Matching Placebo (a Single Dose Cohorts) | 0/14 (0%) | 0/14 (0%) | 2/14 (14.3%) |
| Multiple Doses MT-1186 (Part 2, Cohort M1) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Multiple Doses MT-1186 (Part 2, Cohort M2) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Matching Placebo (Multiple Doses Cohorts) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Event | A Single Dose MT-1186 (Part 1, Cohort S1) | A Single Dose MT-1186 (Part 1, Cohort S2) | A Single Dose MT-1186 (Part 1, Cohort S3) | A Single Dose MT-1186 (Part 1, Cohort S4) | A Single Dose MT-1186 (Part 1, Cohort S5) | A Single Dose MT-1186 (Part 1, Cohort S6) | A Single Dose MT-1186 (Part 1, Cohort S7) | Matching Placebo (a Single Dose Cohorts) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) | Matching Placebo (Multiple Doses Cohorts) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 2/6 | 0/14 | 0/6 | 1/6 | 0/6 |
| ConjunctivitisInfections and infestations | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/14 | 0/6 | 0/6 | 0/6 |
| NasopharyngitisInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/14 | 0/6 | 0/6 | 0/6 |
| Dizziness posturalNervous system disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/14 | 1/6 | 0/6 | 0/6 |
| PresyncopeNervous system disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/14 | 0/6 | 0/6 | 0/6 |
| PyrexiaGeneral disorders | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/14 | 0/6 | 0/6 | 0/6 |
| EnterocolitisGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/14 | 1/6 | 0/6 | 0/6 |
| Hepatic function abnormalHepatobiliary disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/14 | 1/6 | 0/6 | 0/6 |
| Rash pruriticSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/14 | 0/6 | 0/6 | 1/6 |
| Blood creatine phosphokinase increasedInvestigations | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/14 | 0/6 | 1/6 | 0/6 |
| Age, Categorical(Participants) | A Single Dose MT-1186 (Part 1, Cohort S1) | A Single Dose MT-1186 (Part 1, Cohort S2) | A Single Dose MT-1186 (Part 1, Cohort S3) | A Single Dose MT-1186 (Part 1, Cohort S4) | A Single Dose MT-1186 (Part 1, Cohort S5) | A Single Dose MT-1186 (Part 1, Cohort S6) | A Single Dose MT-1186 (Part 1, Cohort S7) | Matching Placebo (a Single Dose Cohorts) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) | Matching Placebo (Multiple Doses Cohorts) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 14 | 6 | 6 | 6 | 74 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | A Single Dose MT-1186 (Part 1, Cohort S1) | A Single Dose MT-1186 (Part 1, Cohort S2) | A Single Dose MT-1186 (Part 1, Cohort S3) | A Single Dose MT-1186 (Part 1, Cohort S4) | A Single Dose MT-1186 (Part 1, Cohort S5) | A Single Dose MT-1186 (Part 1, Cohort S6) | A Single Dose MT-1186 (Part 1, Cohort S7) | Matching Placebo (a Single Dose Cohorts) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) | Matching Placebo (Multiple Doses Cohorts) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 14 | 6 | 6 | 6 | 74 |
| Race/Ethnicity, Customized(Participants) | A Single Dose MT-1186 (Part 1, Cohort S1) | A Single Dose MT-1186 (Part 1, Cohort S2) | A Single Dose MT-1186 (Part 1, Cohort S3) | A Single Dose MT-1186 (Part 1, Cohort S4) | A Single Dose MT-1186 (Part 1, Cohort S5) | A Single Dose MT-1186 (Part 1, Cohort S6) | A Single Dose MT-1186 (Part 1, Cohort S7) | Matching Placebo (a Single Dose Cohorts) | Multiple Doses MT-1186 (Part 2, Cohort M1) | Multiple Doses MT-1186 (Part 2, Cohort M2) | Matching Placebo (Multiple Doses Cohorts) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 2 | 0 | 0 | 0 | 8 |
| Asian (Japanese) | 6 | 6 | 6 | 6 | 6 | 6 | 0 | 12 | 6 | 6 | 6 | 66 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2018 to primary completion in Aug 2018, 4 months.
Results were first posted in Aug 2024, 5 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Edaravone